CTIS2022-503004-24-00招募中1 期
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults =65 Years of Age - V118_24
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 35,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 65 至 65+（—）
- 性别
- All
入选标准
- •1. Adults of =65 years of age on the day of vaccination., 2. Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry., 3. Individuals who have the ability to comply with study procedures including follow-up.
排除标准
- •1. Bedridden subjects (i.e. confined to bed by sickness or old age)., 10. Acute (severe) febrile illness., 11. Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study., 12. Study personnel or immediate family members (brother, sister, child, parent) or the spouse of study personnel., 13. Participation in the current study for more than one season., 2. Subjects that are incapacitated and because of that in need of a Legally Authorized Representative., 3. Receipt of any influenza vaccine within 6 months prior to enrollment or any plan to receive influenza vaccine while participating in the study., 4. Hypersensitivity, including allergy, to any component of vaccines whose use is foreseen in this study, or severe allergic reaction (e.g. anaphylaxis) to previous influenza vaccination., 5. Known history of Guillain-Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis., 6. Clinical conditions representing a contra-indication to intramuscular administration of vaccines or blood draw., 7. Abnormal function of the immune system resulting from: a. Clinical conditions; b. Systemic administration of corticosteroids (PO/IV/IM)8 at a dose =20 mg/day of prednisone (or equivalent) for more than 14 consecutive days within 90 days prior to informed consent; Topical, inhaled and intranasal corticosteroids are permitted. Intermittent use (one dose in 30 days) of intra-articular corticosteroids are also permitted; c. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent;, 8. Receipt of immunoglobulins or any blood products within 180 days prior to informed consent;, 9. Receipt of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the study vaccination, or planned use during the entire study period.
研究者
相似试验
进行中（未招募）
1 期
Study to assess the immunogenicity and safety of GSK's meningococcal group B vaccine when administered concomitantly with GSK's meningococcal MenACWY conjugate vaccine in healthy subjects of 16-18 years of age.Active immunization against invasive meningococcal disease caused by 5 different serogroups of N. meningitidis by concomitant administration of meningococcal group B vaccine and meningococcal MenACWY conjugate vaccineMedDRA version: 20.0Level: PTClassification code 10027199Term: MeningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003722-16-ITGLAXOSMITHKLINE BIOLOGICALS945
进行中（未招募）
不适用
A study to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.Influenza, humanEUCTR2014-003768-19-Outside-EU/EEACSL Limited1,350
进行中（未招募）
不适用
Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and AgrifluPrevent the attack rates of influenza during both pandemic and interpandemic periods..EUCTR2014-005053-40-Outside-EU/EEAovartis Vaccines and Diagnostics S.r.l5,750
进行中（未招募）
不适用
A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thiomersal-containing vaccines in young adult (18 to 60 years) and elderly subjects (over 60 years) - FLU-Q-TIV-TF-003 PRIEUCTR2008-001445-26-EEGlaxoSmithKline Biologicals1,540
进行中（未招募）
不适用
To Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with One Dose of Licensed Meningococcal ACWY Conjugate administered to Healthy Children 2-10 Years of Age.Prophylaxis for Neisseria meningitidis serogroup A, C, W, and YEUCTR2014-005161-72-Outside-EU/EEAovartis Vaccines & Diagnostics2,820